Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Treatment Transporter

The molecular system that shepherds antibodies from a mother’s milk to her baby’s bloodstream may soon provide a painless alternative to drug injections. Molecules in the lining of a baby’s digestive tract pull antibodies from milk before they’re digested and escort them to the blood. This mechanism also operates in the upper-lung and nasal passages, and it remains active throughout life. Syntonix Pharmaceuticals of Waltham, MA, plans to exploit the pathway by fusing antibodies to drug molecules that are conventionally delivered by injection. Entering the body via an inhaler, nasal spray, or a pill, the fused drug molecule takes the antibody shortcut to the bloodstream, says Alan Bitonti, the company’s vice president for research. Last year, Syntonix began a human trial of a fused version of the red-blood-cell booster erythropoietin; several other fused drugs are in preclinical testing.

0 comments about this story. Start the discussion »

Tagged: Web

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me